BioNTech executive says it is too early to predict China vaccine approval

This post was originally published on this site

“We have seen some positive re-engagement, as has been reported. We confirm that we have been taking part in some discussions, which are very positive,” Chief Strategy Officer Ryan Richardson said in an analyst call.

He added it was too early to predict the extent or the timing of such an approval for foreigners working in China.

BioNTech shares rose on Friday after German Chancellor Olaf Scholz announced an agreement to let expatriates in China use the vaccine and he pressed for Beijing to allow the shot to be made freely available to Chinese citizens.